
Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification
The IsoPSA prostate cancer test has shown to reliably maintain risk stratification over 30 months, with low-risk patients with prostate cancer remaining stable. This reinforces its value in both early detection and active surveillance strategies.1 Compared …